Global News

PPD acquires Acurian

Tuesday, August 27, 2013 10:20 AM

Wilmington, N.C.-based CRO Pharmaceutical Product Development (PPD) has acquired Acurian, a provider of clinical trial patient enrollment and retention solutions for the life sciences industry. 

More... »

MedImmune acquires Amplimmune

Monday, August 26, 2013 12:24 PM

AstraZeneca has announced that MedImmune, its global biologics R&D arm, has agreed to acquire Amplimmune, a privately-held, Maryland-based biologics company focused on developing novel therapeutics in cancer immunology.

More... »

Vince & Associates expands early phase gastrointestinal capabilities

Monday, August 26, 2013 12:20 PM

Vince & Associates Clinical Research, a provider of early phase clinical research services to the global biopharmaceutical industry, has expanded its capabilities in the gastrointestinal (GI) therapeutic area with the addition of a dedicated endoscopy suite at its Clinical Pharmacology Unit.

More... »

Immune Pharmaceuticals, EpiCept complete merger

Monday, August 26, 2013 12:15 PM

Immune Pharmaceuticals has completed its merger with EpiCept. The merger combines Immune's antibody therapeutic platform focused on the treatment of inflammatory diseases and cancer with EpiCept's early-stage cancer program and its late-stage topical pain product, AmiKet.

More... »

Icon launches risk-based monitoring service

Monday, August 26, 2013 12:12 PM

Global CRO Icon has launched ICONIK Monitoring, the first in a series of new services that will leverage its ICONIK technology platform.

More... »

Sticares InterACT receives French research tax credit approval

Monday, August 26, 2013 12:11 PM

Sticares InterACT, an internationally operating contract service provider specializing in cardiovascular and metabolic diseases, has been awarded the French research tax credit approval, which it has been holding since 2009. This approval has now been extended for the years 2013, 2014 and 2015.

More... »

CeMM, Haplogen make collection of human cell lines available

Monday, August 26, 2013 12:09 PM

Haplogen, a biotechnology company developing antiviral therapies, and CeMM, the Center for Molecular Medicine of the Austrian Academy of Sciences, are making available their large collection of human cell lines that are deficient for single genes, which they have been building over the past three years as part of a public-private partnership. The partnership, through Haplogen, will distribute requested cell lines to the research community.

More... »

Amgen to acquire Onyx Pharmaceuticals

Monday, August 26, 2013 12:07 PM

Amgen will acquire San Francisco, Calif.-based Onyx Pharmaceuticals, purchasing all of the outstanding shares of Onyx for $125 per share in cash, for a total purchase price of $10.4 billion, or $9.7 billion net of estimated Onyx cash. The boards of both companies have approved the transaction.

More... »

Nuvilex restructures for biotechnology focus

Friday, August 23, 2013 12:36 PM

Nuvilex, an international biotechnology company and former provider of natural products, as well as cell and gene therapy solutions for the treatment of diseases, has restructured corporate operations in an effort to focus on its biotechnology core businesses.

More... »

Mayo Clinic to open Phoenix stem cell lab

Friday, August 23, 2013 12:32 PM

Mayo Clinic in Arizona will open its own stem cell laboratory in summer 2014. The laboratory will be initially dedicated to storing and processing stem cells used for bone marrow transplants at Mayo Clinic Hospital and Phoenix Children's Hospital.

More... »